Characteristics | Overall (n = 19) | A (≥65) | B (≥75) |
---|---|---|---|
Age | 72 (65–81) | 69 (65–73) | 77 (75–81) |
Gender, n (%) | |||
Male | 10 (52.6 %) | 7 (36.8 %) | 3 (15.8 %) |
Female | 9 (47.4 %) | 5 (26.3 %) | 4 (21.1 %) |
Heavy chain, n (%) | |||
IgG | 9 (47.4 %) | 6 (31.6 %) | 3 (15.8 %) |
IgA | 6 (31.6 %) | 3 (15.8 %) | 3 (15.8 %) |
Light chain, n (%) | |||
κ light chain | 1 (5.3 %) | 1 (5.3 %) | 0 |
λ light chain | 2 (10.6 %) | 1 (5.3 %) | 1 (5.3 %) |
β2MG ≥ 5.5 mg/l, n (%) | 14 (73.7 %) | 10 (52.6 %) | 4 (21.1 %) |
Sites of EMP, n (%) | |||
1. Spinal canal | 10 (52.6 %) | 8 (42.1 %) | 2 (10.5 %) |
2. Pleura | 5 (26.3 %) | 0 | 5 (26.3 %) |
3. Soft tissue | 2 (10.5 %) | 2 (10.5 %) | 0 |
More than two sites, n (%) | 4 (21.1 %) | 4 (21.1 %) | 0 |
Plasma cell percentage, n (%) | 37.2 (2–91) | 37 (2–91) | 37.5 (18.5–46.5) |
Abnormal genetics testing, n (%) | |||
G-banded karyotype testing | 2 (33.3 %) | 1 (16.7 %) | 1 (16.7 %) |
FISH | 4 (66.7 %) | 0 | 4 (66.7 %) |